HSP90 inhibition has been shown to be effective in treating lymphomas15–17, AML18–21, CML 26–28, and myeloproliferative neoplasms24. This evidence concerns the gene HSP90AA1 and chronic myelogenous leukemia, BCR-ABL1 positive.